These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24569129)

  • 21. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
    Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study.
    Khindri S; Sabo R; Harris S; Woessner R; Jennings S; Drollmann AF
    BMC Pulm Med; 2011 May; 11():31. PubMed ID: 21615886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study.
    Blais CM; Davis BE; Cockcroft DW
    Respir Res; 2017 Aug; 18(1):146. PubMed ID: 28768531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seebri Neohaler and Utibron Neohaler for COPD.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
    [No Abstract]   [Full Text] [Related]  

  • 27. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
    Wedzicha JA; Banerji D; Chapman KR; Vestbo J; Roche N; Ayers RT; Thach C; Fogel R; Patalano F; Vogelmeier CF;
    N Engl J Med; 2016 Jun; 374(23):2222-34. PubMed ID: 27181606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
    Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
    Banerji D; Fogel R; Patalano F
    Drug Discov Today; 2018 Jan; 23(1):196-203. PubMed ID: 29079130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly: Is It Safe? An Electrocardiographic Evaluation.
    Spannella F; Giulietti F; Cesari V; Francioso A; Cocci G; Landi L; Lombardi FE; Borioni E; Bernardi B; Rosettani G; Bordoni V; Iacoacci C; Giordano P; Sarzani R
    Respiration; 2018; 95 Suppl 1():22-29. PubMed ID: 29705783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
    Mahler DA; Decramer M; D'Urzo A; Worth H; White T; Alagappan VK; Chen H; Gallagher N; Kulich K; Banerji D
    Eur Respir J; 2014 Jun; 43(6):1599-609. PubMed ID: 24176997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
    Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study.
    Chuchalin AG; Tsoi AN; Richter K; Krug N; Dahl R; Luursema PB; Cameron R; Bao W; Higgins M; Woessner R; van As A
    Respir Med; 2007 Oct; 101(10):2065-75. PubMed ID: 17643277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
    Watz H; Mailänder C; Baier M; Kirsten A
    BMC Pulm Med; 2016 Jun; 16(1):95. PubMed ID: 27301417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
    Yang WH; Martinot JB; Pohunek P; Beier J; Magula D; Cameron R; Owen R; Higgins M
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
    Rodrigo GJ; Plaza V
    Chest; 2014 Aug; 146(2):309-317. PubMed ID: 24556877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indacaterol/glycopyrronium affects lung function and cardiovascular events in patients with chronic obstructive pulmonary diseases: A meta-analysis.
    Zhang Q; Zhang H; Wang J; Ruan Z; Dai Y; Xia Z; Lv Q
    Heart Lung; 2021; 50(4):532-541. PubMed ID: 33865004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
    Reisner C; Miller J; DePetrillo P; Maes A; Siddiqui S; Martin UJ
    Pulm Pharmacol Ther; 2018 Dec; 53():33-38. PubMed ID: 30218695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.